Status:
TERMINATED
Nutritive Effects of Cow's Milk-Based Formulas Through 18 Months of Age
Lead Sponsor:
Mead Johnson Nutrition
Collaborating Sponsors:
University of North Carolina, Chapel Hill
Conditions:
Nutritive Effects on Brain Myelination
Eligibility:
All Genders
3-180 years
Phase:
NA
Brief Summary
This clinical trial will assess nutritive effects on brain myelination in infants assigned to receive one of two study formula or mother's own breast milk through 18 month's of age.
Eligibility Criteria
Inclusion
- Singleton birth
- Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age)
- Birth weight of 2500 g (5 lbs 8 oz) or more
- Parent(s) or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study
- Signed informed consent obtained for infant's participation in the study
- Signed authorization obtained to use and/or disclose Protected Health Information for infant from birth through 18 months of age
- Infants receiving formula:
- 3 to 60 days of age at randomization, inclusive (day of birth is considered day 0)
- Exclusively receiving infant formula for at least 72 hours prior to randomization
- Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period
- Infants receiving human milk:
- 150-180 days of age at registration, inclusive (day of birth is considered day 0)
- Mother has intention to predominately provide mother's own breast milk through at least 10 months of age
Exclusion
- Contraindication to magnetic resonance imaging (MRI)
- First degree relative with known autism, intellectual disability, schizophrenia, or bipolar disorder or an inherited disorder of myelination
- Major pre- and/or perinatal issues (such as maternal pre-eclampsia, placental abruption, maternal alcohol or illicit drug use during pregnancy)
- Major delivery complications (such as neonatal hypoxia or neonatal illness requiring a greater than 2-day NICU stay)
- Infant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as combined immunodeficiencies, DiGeorge syndrome, Wiskott-Aldrich syndrome, severe congenital neutropenia and secondary immunodeficiencies linked to HIV infection, Down syndrome or others)
- 5 minute APGAR \< 7
- Infant was born large for gestational age (LGA) (as confirmed by the hospital birth records) from mother who was diabetic at childbirth
- Infant has been identified with inadequate weight gain or failure to thrive by a health care professional (HCP)
- History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant
- Parent(s) or legal guardian unable to speak English at a level to provide informed consent
- Infants receiving formula:
- • Evidence of feeding difficulties or history of formula intolerance, such as vomiting or poor intake at time of randomization
- Infants receiving human milk:
- • Use of infant formula and/or donor milk more than three times per week prior to registration
Key Trial Info
Start Date :
August 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04859231
Start Date
August 5 2021
End Date
September 7 2021
Last Update
January 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599